Tyvaso

Tyvaso is a brand name of treprostinil, approved by the FDA in the following formulation(s):

TYVASO (treprostinil sodium - solution; inhalation)

• 
  Manufacturer: UNITED THERAP
  
  Approval date: July 30, 2009
  
  Strength(s): EQ 0.6MG BASE/ML ^[RLD]

Has a generic version of Tyvaso been approved?

No. There is currently no therapeutically equivalent version of Tyvaso available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tyvaso. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of treating pulmonary hypertension with benzidine prostaglandins
  Patent 5,153,222
  Issued: October 6, 1992
  Inventor(s): Tadepalli; Anjaneyulu S. & Long; Walker A. & Crow; James W. & Klein; Kenneth B.
  Assignee(s): Burroughs Wellcome Co.
  The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
  
  Patent expiration dates:
  
  
  • October 16, 2014
    
    ✓ 
    Patent use: TREATMENT OF PULMONARY HYPERTENSION
  
  



• 
  Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
  Patent 6,521,212
  Issued: February 18, 2003
  Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
  Assignee(s): United Therapeutics Corporation
  A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
  
  Patent expiration dates:
  
  
  • November 13, 2018
    
    ✓ 
    Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
  
  



• 
  Method for delivering benzindene prostaglandins by inhalation
  Patent 6,756,033
  Issued: June 29, 2004
  Inventor(s): Gilles; Cloutier & James; Crow & Michael; Wade & Richard E.; Parker & James E.; Loyd
  Assignee(s): United Therapeutics Corporation
  A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation compared to parenterally administered UT-15 in sheep with induced pulmonary hypertension.
  
  Patent expiration dates:
  
  
  • November 13, 2018
    
    ✓ 
    Patent use: TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
  
  



• 
  Process for stereoselective synthesis of prostacyclin derivatives
  Patent 6,765,117
  Issued: July 20, 2004
  Inventor(s): Robert M.; Moriarty & Raju; Penmasta & Liang; Guo & Munagala S.; Rao & James P.; Staszewski
  Assignee(s): United Therapeutic Corporation
  An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF1-type compounds.
  
  Patent expiration dates:
  
  
  • October 24, 2017
    
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 30, 2012 - NEW DOSAGE FORM
  
  
  • July 30, 2016 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Tyvaso Consumer Information (Drugs.com)
• Tyvaso Inhalation Solution Consumer Information (Wolters Kluwer)
• Tyvaso Consumer Information (Cerner Multum)
• Tyvaso Refill Kit Consumer Information (Cerner Multum)
• Tyvaso Starter Kit Consumer Information (Cerner Multum)
• Tyvaso Advanced Consumer Information (Micromedex)
• Treprostinil Inhalation Solution Consumer Information (Wolters Kluwer)
• Treprostinil Solution Consumer Information (Wolters Kluwer)
• Treprostinil Consumer Information (Cerner Multum)
• Treprostinil inhalation Consumer Information (Cerner Multum)
• Treprostinil injection Consumer Information (Cerner Multum)
• Treprostinil Inhalation Advanced Consumer Information (Micromedex)
• Treprostinil Injection Advanced Consumer Information (Micromedex)
• Treprostinil Sodium AHFS DI Monographs (ASHP)